Givastomig Clinical Trials (2026): 2 Studies for Solid Tumor & Metastatic Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 Givastomig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Solid Tumor & Metastatic Cancer) and 510 total planned enrollment. 2 Givastomig clinical trials are actively recruiting at 9 U.S. sites across 6 states. Most recent activity: NCT07432295 (Aug 2030).
Where to Participate: All Givastomig Trial Sites in the U.S. (9 sites across 6 states)
Every actively recruiting Givastomigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | I-Mab Site 1016 | Goodyear85338 | NCT07432295 | Map |
| CA | I-MAB Site 1005 | Duarte91010 | NCT07432295 | Map |
| CA | Stern Center for Cancer Clinical Trials and Research | Orange92868 | NCT04900818 | Map |
| CO | UCHealth Cancer Care - Anschutz Medical Campus | Aurora80045 | NCT04900818 | Map |
| MA | I-Mab Site 1002 | Boston02114 | NCT07432295 | Map |
| MA | Mass General Hospital | Boston02114 | NCT04900818 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04900818 | Map |
| NY | NYU Langone | New York10016 | NCT04900818 | Map |
| WI | UW Carbone Cancer Center | Madison53705 | NCT04900818 | Map |
Givastomig clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
| P2 | 1 | 1 |
Recruiting Givastomig clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07432295 | GIVA-2Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | P2 | Solid Tumor | 180 | Feb 2026 |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | P1 | Solid Tumor | 330 | Jun 2021 |
Givastomig pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| GIVA-2 | NCT07432295 | P2 | recruiting | Solid Tumor | 180 | — |
All Givastomig trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07432295 | GIVA-2 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | P2 | recruiting | 180 | I-Mab Biopharma US Limited | Feb 2026 |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | P1 | recruiting | 330 | I-Mab Biopharma US Limited | Jun 2021 |
Givastomig clinical trials: frequently asked questions
- How many Givastomig clinical trials are there?
- 2 Givastomig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are Givastomig clinical trials recruiting in 2026?
- Yes — 2 Givastomig trials are actively recruiting in 2026, with 9 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Givastomig being studied for?
- Givastomig is being studied for Solid Tumor, Metastatic Cancer, Advanced Cancer, Esophageal Adenocarcinoma, Gastric Cancer and 3 more. The trials are grouped by indication on this page.
- What phase is Givastomig in?
- Givastomig clinical trials span 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Givastomig clinical trials?
- The lead sponsor across the most Givastomig trials is I-Mab Biopharma US Limited. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Givastomigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: